Computational Molecular Biology 2016, Vol.6, No.1, 1-20
19
Skaar J. R., Pagan J. K., and Pagano M., 2014, SCF ubiquitin ligase-targeted therapies. Nature Reviews Drug Discovery, 13(12): 889–903.
Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., and Langston S.P., 2009, An inhibitor of NEDD8-activating enzyme as a new
approach to treat cancer. Nature, 458(7239): 732–736.
Sun S., 2010, Non-canonical NF- κ B signaling pathway. Nature Publishing Group, 21(1): 71–85.
Sun S., 2012, The noncanonical NFkB Pathway. Immunol Rev., 246(1): 125–140.
Tak P.P., and Firestein G.S., 2001, NFκB in defense and disease : a key role in inflammatory diseases, J Clin Invest. 107(1): 7–11.
Tan J.M.M., Wong E.S.P., and Lim K.L. (2009). Protein Misfolding and Aggregation in Parkinson’s Disease. Antioxidants and Redox Signaling, 11(9):
2119–2134.
Tanaka A., 2010, Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network.
FEBS Letters, 584(7): 1386–1392.
Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., and Ohtsubo M., 1999, MDM2 interacts with MDMX through their RING finger domains.
FEBS Letters, 447(1): 5–9.
Tay S., Hughey J.J., Lee T.K., Lipniacki T., Quake S.R., and Covert M.W., 2010, Single-cell NF-κB dynamics reveal digital activation and analogue information
processing. Nature, 466(7303): 267–271.
Van Drie J.H., 2007, Computer-aided drug design: the next 20 years. Journal of Computer-Aided Molecular Design, 21(10-11): 591–601.
Verdine G.L., and Hilinski G.J., 2012, Stapled Peptides for Intracellular Drug Targets. In Methods Enzymology (pp. 3–33).
Verma J., Khedkar V., and Coutinho E., 2010, 3D-QSAR in Drug Design - A Review. Current Topics in Medicinal Chemistry, 10(1): 95–115.
Vyas V., Ukawala R., Chintha C., and Ghate M., 2012, Homology modeling a fast tool for drug discovery: Current perspectives. Indian Journal of
Pharmaceutical Sciences, 74(1)
Wade M., Wang,Y.V, and Wahl G.M., 2010, The p53 orchestra : Mdm2 and Mdmx set the tone. Trends in Cell Biology, 20(5): 299–309.
Walensky L.D., and Bird G.H., 2014, Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress. Journal of Medicinal Chemistry, 57(15): 6275–6288.
Wang W., Qin J.J., Voruganti S., Srivenugopal K.S., Nag S., Patil S., and Zhang R., 2014, The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent
therapeutic effects in breast cancer models. Nature Communications, 5: 5086.
Welcker M., and Clurman B.E., 2008, FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews
Cancer, 8(2): 83–93.
Wu H., and Arron J.R., 2003, TRAF6 , a molecular bridge spanning adaptive immunity , innate immunity and osteoimmunology, Bioessays, 25(11):1096-105.
Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., and Kollias G., 2004, Tumor necrosis factor (TNF) receptor shedding controls
thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. The Journal of Experimental
Medicine, 200(3): 367–76.
Yang G., Ayala G., De Marzo A., Tian W., Frolov A., Wheeler T.M., and Harper J.W., 2002, Elevated Skp2 protein expression in human prostate cancer:
association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clinical Cancer Research : An
Official Journal of the American Association for Cancer Research, 8(11): 3419–26.
Yang W.L., Wang J., Chan C.H., Lee S.W., Campos A.D., Lamothe B., and Lin H.K., 2009, The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation.
Science, 325(5944): 1134–1138.
Yang Y., Kitagaki J., Wang H., Hou D.X., and Perantoni A.O., 2008, Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Science, 100(1):
24-8.
